Background-Heart failure is a major cause of morbidity and mortality worldwide. The ubiquitously expressed cytokine transforming growth factor-␤1 (TGF␤1) promotes cardiac fibrosis, an important component of progressive heart failure. Membrane-associated endoglin is a coreceptor for TGF␤1 signaling and has been studied in vascular remodeling and preeclampsia. We hypothesized that reduced endoglin expression may limit cardiac fibrosis in heart failure. Methods and Results-We first report that endoglin expression is increased in the left ventricle of human subjects with heart failure and determined that endoglin is required for TGF␤1 signaling in human cardiac fibroblasts using neutralizing antibodies and an siRNA approach. We further identified that reduced endoglin expression attenuates cardiac fibrosis, preserves left ventricular function, and improves survival in a mouse model of pressure-overloadinduced heart failure. Prior studies have shown that the extracellular domain of endoglin can be cleaved and released into the circulation as soluble endoglin, which disrupts TGF␤1 signaling in endothelium. We now demonstrate that soluble endoglin limits TGF␤1 signaling and type I collagen synthesis in cardiac fibroblasts and further show that soluble endoglin treatment attenuates cardiac fibrosis in an in vivo model of heart failure. Conclusion-Our results identify endoglin as a critical component of TGF␤1 signaling in the cardiac fibroblast and show that targeting endoglin attenuates cardiac fibrosis, thereby providing a potentially novel therapeutic approach for individuals with heart failure. (Circulation. 2012;125:2728-2738.)
H eart failure is a major cause of morbidity and mortality that affects Ͼ24 million individuals worldwide. [1] [2] [3] Regardless of the injurious mechanism, a decline in left ventricular (LV) function increases LV pressure and activates several signaling cascades that promote cardiomyocyte hypertrophy and cardiac fibrosis, a process known as cardiac remodeling. At each phase of cardiac remodeling, from acute load to compensatory hypertrophy, various signaling cascades are implicated. 4 Among these, transforming growth factor-␤1 (TGF␤1) is a profibrogenic cytokine that contributes to multiple fibroproliferative disorders, including cardiac fibrosis associated with heart failure. 5 In response to angiotensin II, TGF␤1 expression is increased, converts fibroblasts into myofibroblasts, and generates extracellular matrix proteins such as type I collagen. 6 Excess collagen deposition exaggerates mechanical stiffness of the LV, impairs myocyte contractility, disrupts electric coupling, and worsens tissue hypoxia, 4 thereby promoting heart failure. Given its central role in stimulating fibrosis, TGF␤1 has been nonselectively targeted in heart failure models using multiple approaches, none of which has produced clearly beneficial therapeutic effects. 7, 8 
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TGF␤1 signals through a heteromeric receptor complex comprising a type II ligand binding receptor in association with a type I activin-like kinase (ALK) signaling receptor. Once activated by TGF␤1, this receptor complex triggers phosphorylation of downstream effector proteins known as Smads (canonical pathway) or mitogen-activated protein kinases (noncanonical pathway). Specifically, TGF␤1-induced phosphorylation of Smad-2/3 promotes type I collagen synthesis and fibrosis. 5, 6 Endoglin (CD105) is a 180-kDa homodimeric glycoprotein that serves as a coreceptor for TGF␤1 signaling. Over the past 2 decades, several lines of evidence have suggested that endoglin plays a critical role in vascular remodeling. First, loss-offunction mutations in human endoglin result in the autosomal dominant vascular dysplastic syndrome hereditary hemorrhagic telangiectasia type 1, characterized by endoglin haploinsufficiency and visceral arteriovenous malformations. 9 Second, endoglin-null mice die at embryonic day 10.5 as a result of impaired cardiovascular development and extraembryonic angiogenesis. 10 However, endoglin-heterozygous mice (Eng ϩ/Ϫ ) are viable, have reduced levels of endoglin, and have a phenotype that recapitulates that of hereditary hemorrhagic telangiectasia type 1. 11 The role of endoglin as a modulator of TGF␤1 signaling in heart failure, where fibrosis plays a major role, has not been explored to date.
The extracellular domain of endoglin can be proteolytically cleaved by matrix metalloproteinase-14 and circulates as soluble endoglin (sEng). 12 We recently demonstrated that levels of sEng correlate with clinical measures of heart failure, including LV end-diastolic pressure and New York Heart Association classification. 13 From these observations, we hypothesized that impaired function of the TGF␤1 coreceptor endoglin limits TGF␤1-induced collagen synthesis and cardiac fibrosis, thereby identifying endoglin as a potentially novel therapeutic target in heart failure. To explore this hypothesis, we used a model of pressure-overload-induced heart failure in Eng ϩ/Ϫ mice.
Methods

Reagents
We purchased recombinant human sEng (1-587 amino acids corresponding to the extracellular domain of endoglin; R&D Systems) and recombinant human TGF␤1 (Sigma). Mouse monoclonal antibodies to human endoglin (SC-73934), human type I collagen (SC-80497), human DDR-2 (SC-81707), and fibroblast marker (ER-TR7) were purchased from Santa Cruz. A polyclonal antibody to the N-terminal region of human endoglin (SC-19790) was purchased from Santa Cruz. Goat polyclonal antibodies against mouse endoglin and type I collagen were purchased from R&D Systems (BAF1320) and Santa Cruz (SC-25974), respectively. Polyclonal antibodies to human and mouse phosphorylated Smad (pSmad)-2/3 (AB-3849), pSmad-1 (06 -702), and phosphorylated extracellular regulated kinase (ERK)-1/2 (05-797) were purchased from Millipore; polyclonal antibodies to human and mouse total Smad-2/3 (3102), total Smad-1 (9743), and total ERK (9102) were purchased from Cell Signaling. Rabbit polyclonal antibodies to mouse calcineurin were purchased from Cell Signaling. A rat monoclonal antibody to mouse CD31 was purchased from Pharmingen (01951A). ELISA kits for human and mouse sEng and TGF␤1 were purchased from R&D Systems.
Human LV Tissue Sampling
Viable LV free wall tissue was obtained from human subjects with heart failure (nϭ20) referred for LV assist device (LVAD) placement (HeartMate; Thoratec Corp, Pleasanton, CA). In 7 subjects, an additional LV sample was obtained after LVAD support at the time of cardiac transplantation. Control LV tissue was obtained from the National Disease Research Interchange. All tissue was immediately frozen in liquid nitrogen and stored at Ϫ80°C until further processing as described below. All surgical procedures and tissue harvesting were performed in concordance with the National Institutes of Health and Tufts University Institutional Review Board guidelines.
Mouse Model of Pressure-Overload-Induced Heart Failure
Animals were treated in compliance with the 
Physiological Characterization In Vivo
Transthoracic echocardiography and pressure-volume loop analyses were performed on mice as previously described. 14 -16 
TGF␤1-Induced Type I Collagen Expression in Cardiac Fibroblasts
The Tufts Medical Center Institutional Review Board approved the collection of human tissue for cell culture. Human cardiac fibroblasts (hCFs) were isolated from myocardial tissue harvested during cardiac surgery at Tufts Medical Center, and mouse cardiac fibroblasts (mCFs) were isolated from WT and Eng ϩ/Ϫ mice and stimulated with TGF␤1 for analysis as previously described. 16, 17 
Loss-of-Function Studies in hCFs
For neutralizing antibody studies, hCFs were pretreated with 0.5 g/mL of either an antibody to endoglin or control IgG isotype for 24 hours in fibroblast basal medium without supplementation before stimulation with TGF␤1 (10 ng/mL). After 24 hours, cells were harvested for real-time polymerase chain reaction and Western blot analysis. For endoglin silencing experiments, 50 mol/L siRNA stock (Ambion) was diluted to 1.0 nmol/L in Optimem (Invitrogen) and combined with 2 L lipofectamine (Invitrogen) diluted in 98 L Optimem. After 20 minutes of incubation, cells were exposed to human endoglin siRNA (Ambion; 145527), scrambled siRNA (negative control; Ambion; 4390844), or GAPDH siRNA (positive control; Ambion; 4390850). At various times between 24 and 48 hours after transfection, cells were harvested for analysis.
Recombinant sEng Inhibition of Type I Collagen Synthesis In Vitro
Serum-starved hCFs were treated for 24 hours with recombinant human sEng, stimulated with TGF␤1, and harvested for further analysis.
Overexpression of Human sEng and Full-Length Endoglin In Vitro
For conditioned media studies, COS-1 (American Type Culture Collection) cells were transfected with adenovirus overexpressing human sEng (AdhsEng; generously provided by Dr S.A. Karumanchi) or adenovirus with no transgene for 24 hours. Human sEng levels in conditioned media were confirmed by ELISA. Conditioned media was then transferred into 12-well dishes containing serumstarved hCFs and then stimulated with TGF␤1. For overexpression studies, hCFs were transfected with adenovirus expressing fulllength endoglin (generously provided by Dr Calvin P. Vary), stimulated with TGF␤1, and harvested for analysis.
sEng Inhibits Pressure-Overload-Induced Cardiac Fibrosis
Adult male 14-to 16-week old C57BL/6 mice received intravenous injections of adenovirus with no transgene or AdhsEng 1 day before TAC. Serum levels of human and mouse sEng were quantified by ELISA. Four weeks after TAC, mice were euthanized and tissue was obtained for further analysis.
Real-Time Quantitative Polymerase Chain Reaction
For all cell-based real-time polymerase chain reaction experiments, total RNA was extracted directly with Trizol (Invitrogen) and converted to cDNA with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For all real-time polymerase chain reaction experiments, samples were quantified in triplicate using 40 cycles performed at 94°C for 30 seconds, 60°C for 45 seconds, and 72°C for 45 seconds with an ABI Prism 7900 Sequence Detection System using appropriate primers (see the online-only Data Supplement) as described. 14 -16 Immunoblot Analysis (Western)
Total protein was extracted and quantified from tissue homogenates or cultured cells as described. 14 -16 Immunoblot analysis was then performed as previously described using antibodies for human and mouse targeted proteins.
Histological Quantification of Cardiac Hypertrophy and Fibrosis
LV collagen abundance was quantified by picrosirius red staining as described. 18, 19 Cardiomyocyte cross-sectional area and capillary density were quantified as described. 14 
Statistical Analysis
Results are presented as meanϮSD. Intergroup comparisons were made with 2-factor ANOVA. Two-way ANOVA was performed to examine the effects of cardiac unloading by an LVAD and time on endoglin expression. Repeated-measures ANOVA was used as needed to account for time. All multiple comparisons with a control group were performed with the Dunnett method. Kaplan-Meier analysis with log-rank testing was used for survival analysis. All statistical analyses were performed with SigmaStat version 3.1 (Systat Software, Inc). An ␣ level of PϽ0.05 was considered to indicate a significant effect or between-group difference.
Results
LV Endoglin Expression Is Increased in Human Heart Failure
To determine whether endoglin expression is increased in patients with heart failure, LV samples were obtained from individuals with end-stage heart failure referred for surgical implantation of an LVAD. An additional LV sample was obtained in 7 subjects at the time of cardiac transplantation after LVAD support to examine the effect of hemodynamic unloading on endoglin expression. Compared with subjects without heart failure, endoglin expression was increased in the failing LV at the time of LVAD implantation ( Figure 1A ) and reduced back to control levels after LVAD support ( Figure 1B ). These findings indicate an association between cardiac pressure overload and LV endoglin expression in heart failure. To determine what cardiac cell types express endoglin, cardiomyocytes, fibroblasts, and endothelial cells were next isolated from WT mouse LVs. Endoglin was expressed by cardiac fibroblasts and endothelium but not by cardiac myocytes ( Figure 1C and 1D ).
Increased Membrane-Associated and Circulating Endoglin Expression in Heart Failure
To explore the functional role of endoglin in heart failure, we studied Eng ϩ/Ϫ mice. Compared with WT, LV endoglin expression was lower in Eng ϩ/Ϫ mice ( Figure 2A ). We then used the well-established mouse model of LV pressure overload induced by TAC followed by tissue characterization at 2, 4, and 10 weeks. In WT mice, compared with shamoperated controls, LV endoglin mRNA was increased within 2 weeks and remained elevated at 4 and 10 weeks after TAC ( Figure 2B ). LV endoglin protein expression was similarly increased after 2 and 4 weeks of heart failure and returned to normal levels by 10 weeks in WT mice (data not shown). No change in endoglin levels was observed in the aorta distal to the site of TAC ligature ( Figure IA in the online-only Data Supplement), suggesting a direct effect of cardiac pressure overload on endoglin expression. Serum levels of sEng were also elevated across all time points of pressure-overloadinduced heart failure ( Figure 2C ). TAC also increased LV . A, Endoglin expression in LV tissue from human subjects without heart failure (non-HF) and with heart failure before insertion of a LV assist device (pre-LVAD; *PϽ0.05 vs non-HF). B, LV endoglin expression in 7 subjects before (pre-LVAD) and after (post-LVAD) LVAD support (*PϽ0.05 vs pre-LVAD). Representative Western blots are shown above quantification graphs. C, Representative Western blot of endoglin expression (relative to GAPDH) in isolated mouse endothelium, cardiomyocytes, and cardiac fibroblasts. D, Endoglin mRNA expression by isolated mouse cardiomyocytes and cardiac fibroblasts (***PϽ0.001 between groups).
endoglin mRNA ( Figure 2B ) and circulating sEng levels ( Figure 2C ) in the Eng ϩ/Ϫ mice, but levels were significantly reduced compared with WT mice at each time point.
Reduced Endoglin Expression Preserves LV Function and Promotes Survival in Heart Failure
We next examined the functional impact of reduced endoglin expression in heart failure. Eng ϩ/Ϫ mice demonstrated preserved cardiac function and improved survival (88% versus 50%, respectively; Pϭ0.01) compared with WT mice after TAC (Figure 2D-2F and the Table) . Consistent with these observations, WT mice manifest reduced total body weight at both 4 and 10 weeks after TAC, whereas Eng ϩ/Ϫ mice did not (Table 1) . Compared with baseline values, lung weights were increased in both mouse groups after TAC; however, lung weights were lower after 10 weeks of TAC in Eng ϩ/Ϫ mice compared with WT mice (Table 1) . After 4 weeks of TAC, LV systolic and LV end-diastolic pressures were increased in both WT and Eng ϩ/Ϫ mice compared with the respective sham-operated controls. Although TAC-induced LV systolic pressure was higher in Eng ϩ/Ϫ mice compared with WT mice at both 4 and 10 weeks, LV end-diastolic pressure was not different between WT and Eng ϩ/Ϫ mice at any time point. LV contractility (dP/dtmax) also decreased in a time-dependent manner in WT mice but remained unchanged across all phases of cardiac pressure overload in Eng ϩ/Ϫ mice (the Table) . Echocardiography demonstrated a significant timedependent TAC-induced reduction in LV fractional shortening in WT but not in Eng ϩ/Ϫ mice. After 10 weeks of TAC, WT mice demonstrated greater LV chamber dilatation and lower posterior wall thickness compared with Eng ϩ/Ϫ mice (the Table) . These findings suggest that despite identical degrees of LV pressure overload, reduced endoglin expression in the Eng ϩ/Ϫ mice preserved LV function and improved survival.
Reduced Endoglin Expression Preserves TAC-Induced Cardiomyocyte Hypertrophy and Promotes Myocardial Capillarity
To study the mechanism underlying improved survival in Eng ϩ/Ϫ mice, we first examined changes in cardiac hypertrophy. Across all time points, fold changes in LV mass normalized to tibia length were similar between Eng ϩ/Ϫ and WT mice (the Table) . Cardiomyocyte cross-sectional area was also increased to a similar degree in both WT and Eng ϩ/Ϫ mice after TAC ( Figure 3A and 3B) . Expression of fetal genes and proteins such as ␤-myosin heavy chain, SERCA, and calcineurin demonstrated similar patterns in both WT and Eng ϩ/Ϫ mice after 4 weeks ( Figure 3C-3E ) and 10 weeks ( Figure IIA and IIB in the online-only Data Supplement) of TAC. Next, we observed a significant increase in the capillary-to-cardiomyocyte ratio and total capillary density in both WT and Eng ϩ/Ϫ mice after 4 weeks of TAC. Both measures of myocardial capillarity were higher in Eng ϩ/Ϫ compared with WT mice after TAC ( Figure  3F-3H) . Taken together, these data support that TAC-induced LV hypertrophy is preserved whereas myocardial capillarity is enhanced in Eng ϩ/Ϫ mice compared with WT mice.
Reduced Endoglin Expression Attenuates Cardiac Fibrosis
Compared with controls, TAC induced a time-dependent increase in LV collagen deposition in WT but not Eng ϩ/Ϫ mice ( Figure 4A and 4B) . Type I collagen mRNA expression ( Figure 4C ) and protein expression ( Figure 4D ) were simi- larly increased in WT mice after TAC. Eng ϩ/Ϫ mice exhibited a small increase in type I collagen mRNA after 4 weeks ( Figure 4C ) and 10 weeks ( Figure IIIA in the online-only Data Supplement) and a modest increase in type I collagen protein expression after 10 weeks of heart failure ( Figure 4D ). At all time points, type I collagen mRNA and protein were lower in Eng ϩ/Ϫ mice compared with WT mice. Importantly, similar increases in TGF␤1 mRNA ( Figure 4E ) and active TGF␤1 protein ( Figure 
Canonical and Noncanonical Signaling in Endoglin-Deficient Mice
We next studied the expression of the TGF␤ type I receptors ALK1 and ALK5 in hCFs from fresh tissue samples obtained during cardiac surgery. We observed lower ALK1 mRNA expression in hCFs compared with human umbilical vein endothelial cells, whereas ALK5 expression was similar in both cell types ( Figure IVA Next, we studied phosphorylation of the TGF␤1 noncanonical signaling effector ERK. With an siRNA approach, reduced endoglin expression attenuated TGF␤1-induced phosphorylation of ERK-1/2 in hCFs in vitro ( Figure IVH in the online-only Data Supplement). Consistent with this observation, phosphorylated ERK-1/2 expression was increased in WT mice but not Eng ϩ/Ϫ mice after 4 weeks of TAC ( Figure 4I ). These findings suggest that reduced endoglin expression limits TGF␤1 signaling via Smad-2/3 and ERK.
Membrane-Associated Endoglin Is Required for TGF␤1-Induced Type I Collagen Synthesis
To explore this topic, the role of endoglin was examined by use of a loss-of-function approach in hCFs. Compared with an isotype control antibody, pretreatment of hCFs with an antibody to endoglin attenuated TGF␤1-induced type I collagen mRNA and protein expression ( Figure 5A) . Similarly, silencing en- 
sEng Antagonizes TGF␤1 Signaling in Cardiac Fibroblasts
Previous studies have suggested that sEng attenuates TGF␤1 signaling in endothelium. 20 We next explored whether sEng modulates cardiac fibroblast function. We first treated hCFs with recombinant human sEng and observed a dosedependent decrease in TGF␤1-induced type I collagen expression ( Figure 5D and 5E). To confirm the role of sEng as a negative modulator of TGF␤1 activity, we transfected COS-1 cells with AdhsEng and confirmed a dose-dependent increase in the level of sEng in conditioned culture media ( Figure VB in the online-only Data Supplement). Similar to treatment with recombinant human sEng, treatment of hCFs with conditioned media from AdhsEng-transfected COS-1 cells also inhibited TGF␤1-induced type I collagen and pSmad-2/3 expression ( Figure 5F ). Next, we explored the effect of overexpressing full-length endoglin using an adenovirus-mediated approach (adenovirus expressing full-length endoglin) in hCFs and paradoxically observed a reduction in TGF␤1-induced type 1 collagen expression ( Figure VC in the online-only Data Supplement). To study this further, we measured increased levels of sEng in hCFs transfected with adenovirus expressing full-length endoglin ( Figure VD in the online-only Data Supplement). These findings implicated sEng as a negative feedback mechanism that downregulates TGF␤1 activity in hCFs. 
sEng Attenuates Cardiac Fibrosis in Pressure-Overload-Induced Heart Failure
To explore whether sEng limits cardiac fibrosis in vivo, WT mice received intravenous injections of AdhsEng, which increased circulating levels of human sEng ( Figure 6A ). Compared with controls, treatment with AdhsEng significantly reduced cardiac fibrosis ( Figure 6B ) and LV type I collagen expression ( Figure 6C ) after 4 weeks of TAC. No significant change in LV contractility (data not shown) was observed during this subacute phase of LV pressure overload. These findings support that sEng blocks TGF␤1 signaling and limits cardiac fibrosis in pressure-overload-induced heart failure.
Discussion
Our central finding is that endoglin is required for TGF␤1 signaling in hCFs and that selectively inhibiting TGF␤1 signaling by reducing endoglin activity attenuates cardiac fibrosis and improves survival in a mouse model of heart failure. In contrast to the functional role of endoglin in promoting TGF␤1 signaling, sEng limits TGF␤1 signaling, type I collagen synthesis, and ultimately cardiac fibrosis ( Figure 7) .
Our findings have several important clinical implications. First, previous studies of nonselective TGF␤1 blockade have produced mixed results in heart failure. The ability to selectively modulate TGF␤1 activity by limiting the TGF␤1 coreceptor endoglin offers a potentially novel approach to managing heart failure. Second, studies involving endoglin have focused on vascular remodeling with minimal data exploring the role of endoglin in heart failure. However, endoglin has been shown to mediate collagen synthesis induced by angiotensin II and TGF␤1 in rat cardiac fibroblasts. 21, 22 Our findings confirm that endoglin is an important component of cardiac remodeling both in human LV tissue and cardiac fibroblasts and in a mouse model. Third, recent publications have focused on the role of sEng in preeclampsia, vascular function, and renal fibrosis. We recently identified sEng as a biomarker of heart failure 12 and now describe a functional role for sEng as an autocrine antagonist of TGF␤1 signaling in heart failure. These findings provide new insight into the regulation of TGF␤1 activity in heart failure and further identify sEng as a potentially novel therapeutic approach to limit cardiac fibrosis.
We first identified that cardiac levels of endoglin are increased in subjects with end-stage heart failure referred for mechanical LVAD support and that endoglin levels are reduced by mechanical LV unloading. Previous studies have shown increased cardiac expression of profibrogenic genes, including TGF␤1, in patients with end-stage heart failure referred for LVAD support. 23, 24 In both studies, higher levels of TGF␤1 were observed in subjects requiring LVAD support until cardiac transplantation, suggesting that TGF␤1 may limit myocardial recovery by promoting tissue fibrosis. We now identify endoglin as a potentially important target to limit TGF␤1 activity in heart failure.
Next, by confirming that endoglin is expressed by cardiac fibroblasts, we studied the effect of reduced endoglin expression on cardiac fibrosis in a murine model of heart failure. We first observed increased endoglin expression in the LV with no change in abdominal aortic expression in WT mice subjected to TAC. Importantly, 2 isoforms of membraneassociated endoglin exist, namely the long and the less abundant short isoforms. 25 We confirmed that long endoglin is the dominantly expressed isoform in the mouse LV (data not shown). Consistent with our human observations, we identified that cardiac pressure overload increases endoglin expression in heart failure. Although TAC induced a similar pattern of endoglin expression in Eng ϩ/Ϫ and WT mice, levels of endoglin expression were significantly lower in the Eng ϩ/Ϫ mice throughout. Reduced endoglin expression improved survival in this model of pressure-overload-induced heart failure while preserving cardiomyocyte hypertrophy, modestly increasing myocardial capillarity, and significantly reducing cardiac fibrosis. Collectively, these changes were more consistent with adaptive as opposed to maladaptive cardiac remodeling 26 ; however, the most dramatic observation in this model was the nearly complete attenuation of cardiac fibrosis in the pressure-overloaded myocardium.
We then confirmed the dependence of TGF␤1 signaling on endoglin expression in hCFs using loss-of-function approaches. Furthermore, treatment with sEng either as a recombinant protein or by adenoviral overexpression of sEng or full-length endoglin in vitro mirrored the phenotype of the reduced endoglin levels in the Eng ϩ/Ϫ mice, suggesting that sEng also limits TGF␤1 signaling and type I collagen synthesis. Several prior studies have shown that overexpressing endoglin in rat myoblasts and mouse fibrosarcoma cell lines limits TGF␤1-induced collagen expression. [27] [28] [29] [30] In the context of our findings, these observations may highlight important differences between cell types and species with regards to the biological activity of endoglin. Furthermore, these reports may be consistent with our gain-of-function observations in hCFs and could suggest that transfecting endoglin into stable cell lines also increases levels of soluble endoglin in vitro, thereby attenuating TGF␤1 activity. Finally, we studied a potential role of sEng in pressureoverload-induced heart failure and observed reduced cardiac fibrosis in mice treated with an adenovirus overexpressing human sEng.
Previous studies have highlighted the critical role that TGF␤1 signaling plays in cardiac remodeling and heart failure. 5, 31, 32 Benefits of blocking TGF␤1 activity such as improving diastolic function in hypertensive heart dis- ease 7, 33, 34 have been reported, but in other models of heart failure, this increased mortality after induction of ischemic heart failure. 8, 35 Given the potential for adverse effects of nonselective TGF␤1 blockade, targeting specific aspects of the TGF␤1 signaling cascade may yield better outcomes. Our findings support this concept in that Eng ϩ/Ϫ mice demonstrated reduced phosphorylation of Smad-2/3 in association with LV hypertrophy and limited cardiac fibrosis after TAC. Because endoglin is highly expressed in cardiac fibroblasts, modulating endoglin expression in these cells may selectively influence fibrosis without affecting hypertrophy. This combination results in sustained LV contractility and improved survival despite chronic pressure-overload-induced heart failure.
The role of sEng in heart failure also remains poorly understood. First, the mechanism underlying increased sEng expression in heart failure is unknown. Proteolytic cleavage of sEng from endoglin may occur both locally in cardiac tissue or systemically because levels of matrix metalloproteinase-14 are known to be elevated in heart failure. 11, 16, 36, 37 Second, the mechanism by which elevated sEng levels interrupt TGF␤1 signaling remains poorly characterized. Several possibilities exist ( Figure 7 ). First, endoglin may modulate signaling via several TGF␤ family ligands, 38, 39 and sEng could serve as a ligand trap for TGF␤1 or other ligands, including bone morphometric protein. However, recent studies indicate that bone morphometric protein-9 and -10 may be the only ligands that bind to sEng with high affinity. 40 Second, sEng may promote alternate signaling pathways that indirectly inhibit TGF␤1 signaling such as bone morphometric protein-7. 41 Finally, release of sEng by ectodomain shedding may render the receptor nonfunctional, thereby further limiting TGF␤1 activity in heart failure.
The present study has several limitations. First, we used a mouse model with reduced total body expression of endoglin as opposed to changes in cardiac-restricted expression. Second, as a result of the technical challenges of sustaining elevated levels of exogenous sEng with an adenoviral approach, we were unable to examine whether sEng improves cardiac function in a longer-term model of heart failure.
Conclusions
TGF␤1 is a powerful cytokine that governs the development of cardiomyocyte hypertrophy and cardiac fibrosis in heart failure. Therapies designed to nonselectively block TGF␤1 activity in heart failure have failed to demonstrate clear benefit. We now demonstrate the important functional role of endoglin in heart failure by specifically showing that endoglin facilitates whereas sEng attenuates TGF␤1-mediated cardiac fibrosis and further that reduced endoglin expression can limit cardiac fibrosis, preserve cardiac function, and improve survival in pressure-overload-induced heart failure. Our studies support that targeting endoglin provides a potentially unique and novel therapeutic approach for individuals with heart failure.
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